1. From: Biological Agents for Moderately to Severely Active Ulcerative ColitisA Systematic Review and Network Meta-analysis
Ann Intern Med. 2014;160(10): doi: /M
Figure Legend:
MCS = Mayo Clinic score; RCT = randomized, controlled trial; UC = ulcerative colitis.
Date of download: 10/4/2017
Copyright © American College of Physicians. All rights reserved.

2. From: Biological Agents for Moderately to Severely Active Ulcerative ColitisA Systematic Review and Network Meta-analysis
Ann Intern Med. 2014;160(10): doi: /M
Figure Legend:
Induction phases are represented in blue, whereas maintenance phases are represented in green. ACT = Active Ulcerative Colitis Trial; ADA = adalimumab; eow = every other week; GLM = golimumab; IFX = infliximab; ITT-A3 = intention-to-treat population, after protocol amendment 3; ITT-E = intention-to-treat population, original protocol; IV = intravenous; PBO = placebo; PURSUIT-M = Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment–Maintenance; PURSUIT-SC = Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment–Subcutaneous; q8w = every 8 wk; q4w = every 4 wk; R = randomization; SC = subcutaneous; ULTRA = Ulcerative Colitis Long-Term Remission and Maintenance With Adalimumab; VDZ = vedolizumab.
Date of download: 10/4/2017
Copyright © American College of Physicians. All rights reserved.

3. From: Biological Agents for Moderately to Severely Active Ulcerative ColitisA Systematic Review and Network Meta-analysis
Ann Intern Med. 2014;160(10): doi: /M
Figure Legend:
Green circles signify low risk of bias. ACT = Active Ulcerative Colitis Trial; PURSUIT-SC = Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment–Subcutaneous; ULTRA = Ulcerative Colitis Long-Term Remission and Maintenance With Adalimumab.
Date of download: 10/4/2017
Copyright © American College of Physicians. All rights reserved.

4. From: Biological Agents for Moderately to Severely Active Ulcerative ColitisA Systematic Review and Network Meta-analysis
Ann Intern Med. 2014;160(10): doi: /M
Figure Legend:
Green circles indicate low risk of bias, and red circles signify high risk of bias. ACT = Active Ulcerative Colitis Trial; PURSUIT-M = Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment–Maintenance; ULTRA = Ulcerative Colitis Long-Term Remission and Maintenance With Adalimumab.
Date of download: 10/4/2017
Copyright © American College of Physicians. All rights reserved.

5. From: Biological Agents for Moderately to Severely Active Ulcerative ColitisA Systematic Review and Network Meta-analysis
Ann Intern Med. 2014;160(10): doi: /M
Figure Legend:
Compared treatments are connected indirectly through the placebo, the “common comparator.” The number of independent randomized, controlled trials and number of patients who were naive to biological agents (in parenthesis) for each comparison in the induction treatment network are informed by head-to-head evidence. To calculate the numbers of patients, we considered only persons assigned to a dose as approved in the summary of product characteristics and those assigned to placebo. ADA = adalimumab; GLM = golimumab; IFX = infliximab; PBO = placebo; VDZ = vedolizumab.
Date of download: 10/4/2017
Copyright © American College of Physicians. All rights reserved.

6. From: Biological Agents for Moderately to Severely Active Ulcerative ColitisA Systematic Review and Network Meta-analysis
Ann Intern Med. 2014;160(10): doi: /M
Figure Legend:
Treatment effect estimates come from Bayesian network meta-analysis. Odds ratios >1.0 favor the treatment in the left upper square. To obtain ORs for comparisons in the opposite direction, reciprocals should be calculated. ADA = adalimumab; CrI = credible interval; GLM = golimumab; IFX = infliximab; OR = odds ratio; VDZ = vedolizumab.
Date of download: 10/4/2017
Copyright © American College of Physicians. All rights reserved.